About the Authors
- Andreas Karlsson
-
Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing
* E-mail: andreas.a.karlsson@ki.se
Affiliation Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Alexandra Jauhiainen
-
Roles Conceptualization, Methodology, Project administration, Software, Supervision, Writing – original draft, Writing – review & editing
Affiliation AstraZeneca, Gothenburg, Sweden
- Roman Gulati
-
Roles Conceptualization, Methodology, Software, Validation, Writing – review & editing
Affiliation Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States of America
- Martin Eklund
-
Roles Methodology, Writing – review & editing
Affiliation Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Henrik Grönberg
-
Roles Resources, Writing – review & editing
Affiliations Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden
- Ruth Etzioni
-
Roles Conceptualization, Methodology, Software, Validation, Writing – review & editing
Affiliations Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, United States of America, Department of Health Services, University of Washington, Seattle, United States of America, Department of Biostatistics, University of Washington, Seattle, United States of America
- Mark Clements
-
Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Writing – original draft, Writing – review & editing
Affiliation Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Competing Interests
Author HG has five prostate cancer diagnostic–related patents pending: Prognostic Method for Individuals with Prostate Cancer (EP2922970B1, US20150284804A1), Method for indicating the presence or non-presence of prostate cancer (CA2871877A1, US20150317431A1, EP2922967B1, WO2013172779A3), Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics (WO2018141828A1, US20150317431A1) and Methods and compositions for correlating genetic markers with prostate cancer risk (US9534256B2, WO2009085196A1). Thermo Fisher Scientific is licensing these patent applications and HG might receive royalties from sales related to these patent applications; author ME is named on the first four of the five patent applications. Importantly, the methods disclosed by these patent applications are not part of this research paper. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The commercial appliation with AstraZeneca does not alter our adherence to PLOS ONE policies on sharing data and materials.